Menu Search
Equities

AbbVie Inc

4AB:BRN

AbbVie Inc

Actions
  • Price (CHF)149.69
  • Today's Change0.00 / 0.00%
  • Shares traded890.00
  • 1 Year change+4.56%
  • Beta--
Data delayed at least 15 minutes, as of Apr 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

  • Revenue in USD (TTM)54.32bn
  • Net income in USD4.82bn
  • Incorporated2012
  • Employees50.00k
  • Location
    AbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
  • Phone+1 (847) 932-7900
  • Fax+1 (302) 655-5049
  • Websitehttps://www.abbvie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ABBV:NYQ since
announced		Transaction
value
Cerevel Therapeutics Holdings IncAnnounced06 Dec 202306 Dec 2023Announced15.11%8.62bn
ImmunoGen IncDeal completed30 Nov 202330 Nov 2023Deal completed20.15%10.22bn
Data delayed at least 15 minutes, as of Apr 19 2024 21:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.